Saturday 20 November 2021

Moderna doses first subject in respiratory syncytial virus vaccine trial: expects to enrol nearly 34,000 subjects for the trial, which will be conducted in multiple countries.

Moderna doses first subject in respiratory syncytial virus vaccine trial: expects to enrol nearly 34,000 subjects for the trial, which will be conducted in multiple countries. submitted by /u/shallah
[link] [comments]


from Health https://ift.tt/3HwU7nU
via IFTTT
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)